Home › Compare › RUBY vs EQR

RUBY vs EQR: Dividend Comparison 2026

RUBY yields 3508.77% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RUBY wins by $2034141393542.03M in total portfolio value
10 years
RUBY
RUBY
● Live price
3508.77%
Share price
$0.06
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2034141393542.08M
Annual income
$1,926,153,862,282,748,700.00
Full RUBY calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — RUBY vs EQR

📍 RUBY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRUBYEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RUBY + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
RUBY pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RUBY
Annual income on $10K today (after 15% tax)
$298,245.61/yr
After 10yr DRIP, annual income (after tax)
$1,637,230,782,940,336,400.00/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, RUBY beats the other by $1,637,230,782,940,331,800.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RUBY + EQR for your $10,000?

RUBY: 50%EQR: 50%
100% EQR50/50100% RUBY
Portfolio after 10yr
$1017070696771.07M
Annual income
$963,076,931,141,377,000.00/yr
Blended yield
94.69%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

RUBY
Analyst Ratings
5
Buy
3
Hold
1
Sell
Consensus: Buy
Altman Z
-81.9
Piotroski
2/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RUBY buys
0
EQR buys
0
No recent congressional trades found for RUBY or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRUBYEQR
Forward yield3508.77% ✓5.87%
Annual dividend / share$2.00$3.47 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$2034141393542.08M ✓$47.8K
Annual income after 10y$1,926,153,862,282,748,700.00 ✓$5,475.61
Total dividends collected$2026733119198.63M ✓$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: RUBY vs EQR ($10,000, DRIP)

YearRUBY PortfolioRUBY Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$361,577$350,877.19$11,380$679.82+$350.2K → RUBY
2$12,243,821$11,856,933.69$13,014$837.25+$12.23M → RUBY
3$388,336,948$375,236,059.53$14,961$1,036.20+$388.32M → RUBY
4$11,538,279,357$11,122,758,822.00$17,297$1,289.22+$11538.26M → RUBY
5$321,205,540,543$308,859,581,631.20$20,121$1,613.15+$321205.52M → RUBY
6$8,379,307,864,544$8,035,617,936,162.96$23,561$2,030.84+$8379307.84M → RUBY
7$204,877,671,222,196$195,911,811,807,134.25$27,783$2,573.54+$204877671.19M → RUBY
8$4,695,974,086,156,479$4,476,754,977,948,728.50$33,013$3,284.39+$4695974086.12M → RUBY
9$100,922,926,410,592,910$95,898,234,138,405,470.00$39,547$4,223.51+$100922926410.55M → RUBY
10$2,034,141,393,542,082,800$1,926,153,862,282,748,700.00$47,791$5,475.61+$2034141393542.03M → RUBY

RUBY vs EQR: Complete Analysis 2026

RUBY — Stock

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Full RUBY Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this RUBY vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RUBY vs SCHDRUBY vs JEPIRUBY vs ORUBY vs KORUBY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.